Aortech International PLC
27 March 2000
Completion of Clinical Trials for the TruCCOMS
AorTech International plc. ('AorTech') the Scottish-based
manufacturer of cardiovascular devices, announces the successful
completion of its patient clinical trials at the Papworth Hospital in
the UK in respect of its Continuous Cardiac Output Monitoring System
('TruCCOMS').
Dr. Peter Duijst, AorTech's Medical Director said:
'I am delighted at the successful completion of this clinical trial.
Clinical data from this study is presently being prepared for
submission to the European Regulatory Authorities for CE Mark
approval which we anticipate in the near future. This will enable
AorTech to commence marketing the product in Europe. We have already
received requests to use the product from several major hospitals in
the United Kingdom, Germany and Italy which wish to utilize the
TruCCOMS for their patients in surgery and intensive care because of
its unique clinical benefits.
'The outstanding benefit of TruCCOMS is in its immediate response to
cardiac output changes in patients. The medical community, who deal
with critical and surgical care patients have been seeking a product
which monitors patients cardiac output directly and also enables the
physicians to recognise immediately any changes in cardiac output.
Clinical evaluation of the new TruCCOMS system has demonstrated its
unique performance and safety.'
Bruno Lowinger, Vice President and responsible for the US said:
'The sales and marketing of TruCCOMS represents a major opportunity
for AorTech in the US and we have already established two major
clinical reference centres which have commenced use of the TruCCOMS
product. There is continued interest from US hospitals in becoming
clinical reference sites prior to our major product launch.'
27 March, 2000
Enquiries:
AorTech International plc
Eddie McDaid, Managing Director 01698 746 699
Bruno Lowinger, Vice President +1-734 827 2245
College Hill 0171 457 2020
Michael Padley / Nick Nelson
For further information, visit AorTech's website at www.aortech.com
Copies of this statement will be available for a period of 14 days
from the Company's registered office: Phoenix Crescent, Strathclyde
Business Park, Bellshill, Scotland ML4 3NU.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.